Using MRI to Improve Radiotherapy Planning for Rectal Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the feasibility of acquiring serial MRI images to enhance radiotherapy planning for patients with rectal cancer. By utilizing MRI, which provides superior soft tissue contrast compared to traditional CT scans, the study seeks to improve the accuracy of target volume delineation in radiotherapy. The research focuses on patients with histologically confirmed rectal adenocarcinoma who are scheduled for radical radiotherapy. The study will evaluate whether routine MRI imaging can be effectively integrated into the treatment planning process for locally advanced rectal cancer.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically confirmed rectal adenocarcinoma.
* T stage 3b or above and/or high risk factors eg. EMVI, nodal disease.
* Participant able to give written informed consent.
* Male or non-pregnant female ≥18 years of age.
* Scheduled to undergo radical radiotherapy.
* Patients willing and able to comply with the protocol for the duration of study.

Exclusion Criteria:

* Contra-indications to MRI, such as claustrophobia, excessive body weight, MRI unsafe implants, ferrous metal in the body, insufficient information on prior surgeries. MRI conditional implants where conditions cannot be met (e.g pacemakers).
* Any previous radiotherapy to the pelvis.
* Inflammatory bowel disease.
* Other severe or uncontrolled systemic disease or evidence of any other significant disorder or lab finding that makes it undesirable for the patient to participate in the study, as determined by the treating clinician.
* History of physical or psychiatric disorder that would prevent informed consent and compliance with the protocol.
* Patients with de-functioning stoma.
* Major surgery within 28 days prior to trial entry.

Where it's running

• Beatson West of Scotland Cancer Centre
  Glasgow, United Kingdom Recruiting

Study contacts

• Principal investigator: Ms Lynsey Devlin — NHS Greater Glasgow and Clyde
• Study coordinator: Ms Lynsey Devlin
• Email: lynsey.devlin@nhs.scot
• Phone: 0141 301 9902

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Toripalimab Plus Cetuximab and Irinotecan for second-line right-sided colon cancer

  This phase II study tests whether a combo of toripalimab, cetuximab, and irinotecan helps adults with second-line, right‑sided, RAS/BRAF wild-type advanced colon cancer.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT07896681

• Intratumoral oncolytic virus plus immune checkpoint inhibitors in metastatic colorectal, gastric, or liver cancer

  Doctors are testing whether injecting an oncolytic virus directly into tumors along with immune checkpoint drugs is safe and may help people with advanced colorectal, gastric, or liver cancer who have tried many treatments.

  Recruiting Foshan Fosun Chancheng Hospital · Guangdong, Foshan · NCT07850882

• Targeted alpha-radiation therapy for NTSR1-positive tumors using SKL35501/SKL35502

  This early-phase trial tests whether a two-part approach—an imaging agent to find NTSR1-expressing tumors and a targeted alpha-ray therapy—can be safely used in adults with certain advanced solid tumors.

  Recruiting Phase 1 SK Life Science, Inc. · Glen Burnie, Maryland and 4 other locations · NCT07812805

• Pirfenidone plus PD-1 inhibitor with or without targeted radiotherapy for advanced colorectal cancer

  This study tests whether combining pirfenidone with a PD-1 inhibitor, with or without hypofractionated radiotherapy, is safe and helps people with unresectable or metastatic pMMR/MSS colorectal cancer who have exhausted standard therapies.

  Recruiting Phase 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07644286

• VMD-102 in liver cancer and other solid tumors

  This study tests VMD-102 to see if it is safe and tolerable and to find the best dose for further study in adults with advanced liver cancer and several other solid tumors.

  Recruiting at 2 sites Phase 1/2 VM Discovery, Inc. · Scottsdale, Arizona and 1 other locations · NCT07636785

• First-in-human imaging study of 68Ga-DFC413 and comparison with 68Ga-NNS309 in solid tumors

  This study tests a new radioactive imaging agent, 68Ga-DFC413, to see how it behaves in patients with several solid tumors and compares it to 68Ga-NNS309.

  Recruiting at 2 sites Phase 1 Novartis · Odense C and 1 other locations · NCT07630961

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.